Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Aug 10 2016 Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results Aug 03 2016 Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results Aug 02 2016 Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers Jun 16 2016 Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements Jun 06 2016 Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO May 27 2016 Cyclacel Announces Reverse Stock Split May 19 2016 Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting May 11 2016 Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results May 04 2016 Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results Apr 18 2016 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors Apr 11 2016 Cyclacel Announces Receipt of Nasdaq Extension Mar 24 2016 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results Mar 17 2016 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results Feb 05 2016 Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing Feb 02 2016 Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference Jan 11 2016 Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016 Dec 14 2015 Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium Nov 23 2015 CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models Nov 12 2015 Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results Nov 09 2015 Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference Nov 05 2015 Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results Oct 26 2015 Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference Oct 22 2015 Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors Sep 17 2015 Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas Sep 03 2015 Cyclacel Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Aug 10 2016 Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results Aug 03 2016 Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results Aug 02 2016 Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers Jun 16 2016 Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements Jun 06 2016 Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO May 27 2016 Cyclacel Announces Reverse Stock Split May 19 2016 Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting May 11 2016 Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results May 04 2016 Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results Apr 18 2016 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors Apr 11 2016 Cyclacel Announces Receipt of Nasdaq Extension Mar 24 2016 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results Mar 17 2016 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results Feb 05 2016 Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing Feb 02 2016 Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference Jan 11 2016 Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016 Dec 14 2015 Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium Nov 23 2015 CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models Nov 12 2015 Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results Nov 09 2015 Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference Nov 05 2015 Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results Oct 26 2015 Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference Oct 22 2015 Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors Sep 17 2015 Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas Sep 03 2015 Cyclacel Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page next › Last page last »
Aug 02 2016 Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers
Jun 06 2016 Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO
May 19 2016 Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 18 2016 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors
Dec 14 2015 Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium
Nov 23 2015 CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models
Nov 09 2015 Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference
Oct 26 2015 Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference
Oct 22 2015 Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors
Sep 17 2015 Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas
Sep 03 2015 Cyclacel Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference
